Received Feb 13, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | N77J2 | — |
received Shingrix diluent alone; received Shingrix diluent alone; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate preparation of medication in a 61-year-old female patient who received Herpes zoster (Shingrix) (batch number N77J2, expiry date 23-OCT-2026) for prophylaxis. On 28-JAN-2024, the patient received the 2nd dose of Shingrix. On 28-JAN-2024, an unknown time after receiving Shingrix, the patient experienced inappropriate preparation of medication (Verbatim: received Shingrix diluent alone) and inappropriate dose of vaccine administered (Verbatim: received Shingrix diluent alone). The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were unknown. Additional Information: GSK Receipt Date: 28-JAN-2025 The office manager reported that a patient received second dose of Shingrix diluent alone without the powder, which led to inappropriate preparation of medication and inappropriate dose of vaccine administered. The Vaccine Administration Facility was the same as Primary Reporter.